This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Avantor, Inc. (AVTR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical Group (MD) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MD or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. GDRX: Which Stock Is the Better Value Option?
The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.
Mednax (MD) Q2 Earnings Match Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Healthcare (ACHC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 9.09% and 0.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services
by Zacks Equity Research
Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services are part of Zacks Industry Outlook article.
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech
by Zacks Equity Research
Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.
2 Top Hospital Stocks to Buy Despite Industry Headwinds
by Kaibalya Pravo Dey
Rising supplies expense, wages and benefits, and other operating costs are lowering margins for the Zacks Medical-Hospital industry players. However, Acadia Healthcare and Pediatrix Medical are poised to win big with recovering patient volumes.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio
by Zacks Equity Research
Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
by Zacks Equity Research
Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.
Why Acadia Healthcare (ACHC) Dips 1.6% Despite Q1 Earnings Beat
by Zacks Equity Research
Acadia Healthcare (ACHC) aims to add around 300 beds to its existing facilities in 2022.
Mednax (MD) Down 20% Despite Q1 Earnings Beat on Patient Volumes
by Zacks Equity Research
Mednax (MD) continues to anticipate revenues of $2 billion and adjusted EBITDA of at least $270 million for 2022.
Mednax (MD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 22.22% and 1.75%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Universal Health Services (UHS) Q1 Earnings Miss Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of -12.96% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare (HCA) Q1 Earnings Miss Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of -3.51% and 1.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Universal Health (UHS) Stock Now
by Zacks Equity Research
Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).
Acadia Healthcare (ACHC) Up 10% in 3 Months: More Room to Run?
by Zacks Equity Research
Solid demand for behavioral healthcare services, multiple growth-related initiatives and a solid cash balance are driving Acadia Healthcare (ACHC).
Why Holding Humana (HUM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Banking on better membership and strategic initiatives, Humana (HUM) holds immense potential to reap benefits for investors.